Table II.
Ser326Cys polymorphism of the hOGG1 gene and Arg156Arg polymorphism of the ERCC2/XPD gene in PCa patients.
| Polymorphism genotype or allele | Patients (n=100) | Controls (n=100) | OR | (95% CI) |
|---|---|---|---|---|
| Ser326Cys | ||||
| CC | 22 | 29 | 1.00 | |
| CG | 52 | 57 | 1.20 | (0.59–2.49) |
| GG | 26 | 14 | 2.45 | (0.96–6.31) |
| GG+CG | 78 | 71 | 1.45 | (0.73–2.90) |
| C | 104 | 85 | 1.47 | (0.97–2.22) |
| G | 96 | 115 | 1.00 | |
| Arg156Arg | ||||
| CC | 26 | 38 | 1.00 | |
| AC | 53 | 49 | 1.58 | (0.80–3.13) |
| AA | 21 | 13 | 2.36 | (0.93–6.08) |
| AA+AC | 74 | 62 | 1.74 | (0.92–3.34) |
| C | 95 | 75 | 1.51 | (0.99–2.29) |
| A | 105 | 125 | 1.00 |
hOGG1, human homolog of the 8-oxoguanine DNA glycosylase 1; ERCC2/XPD, excision repair cross-complementing rodent repair deficiency complementation group 2/Xeroderma pigmentosum complementation group D; PCa, prostate cancer; OR, odds ratio; CI, confidence interval.